In animal experiments, the AP-1-M-Dox coupling showed stronger anti-tumor ability and fewer toxic side effects than Dox alone, precisely targeting and killing TCSCs and inhibiting tumor growth, proving that CD133 is a potential target for the elimination of TCSCs Combined aptamer-mediated drug delivery improves the safety of treatment (36). Here, PROM1 is linked to neoplasm.